Supportive Oncodermatology: Addressing dermatologic adverse events associated with oncologic therapies

References

• Miller KD, Siegel RL, Lin CC, et al. Cancer treatment and survivorship statistics, 2016. CA Cancer J Clin. 2016; 66(4): 271–289.
   PubMed Web of Science ®Google Scholar
• Warren JL, Yabroff KR, Meekins A, et al. Evaluation of trends in the cost of initial cancer treatment. J Natl Cancer Inst. 2008; 100: 888–897.
   PubMed Web of Science ®Google Scholar
• Gandhi M, Oishi K, Zubal B, Lacouture ME. Unanticipated toxicities from anticancer therapies: survivors' perspectives. Support Care Cancer. 2010; 18: 1461–1468.
   Web of Science ®Google Scholar
• Balagula Y, Rosen ST, Lacouture ME. The emergence of supportive oncodermatology: the study of dermatologic adverse events to cancer therapies. J Am Acad Dermatol. 2011; 65: 624–635.
   PubMed Web of Science ®Google Scholar
• Chu D, Lacouture ME, Fillos T, Wu S. Risk of hand-foot skin reaction with sorafenib: a systematic review and meta-analysis. Acta Oncol. 2008; 47(2): 176–186.
   PubMed Web of Science ®Google Scholar
• Sawhney R, Kabbinavar F. Angiogenesis and angiogenic inhibitors in renal cell carcinoma. Curr Urol Rep. 2008; 9: 26–33.
   PubMedGoogle Scholar
• Fischer A, Wu S, Ho AL, Lacouture ME. The risk of hand-foot skin reaction to axitinib, a novel VEGF inhibitor: a systematic review of literature and meta-analysis. Invest New Drugs. 2013; 31: 787–797.
   Web of Science ®Google Scholar
• McLellan B, Kerr H. Cutaneous toxicities of the multikinase inhibitors sorafenib and sunitinib. Dermatol Ther. 2011; 24: 396–400.
   PubMed Web of Science ®Google Scholar
• Autier J, Escudier B, Wechsler J, Spatz A, Robert C. Prospective study of the cutaneous adverse effects of sorafenib, a novel multikinase inhibitor. Arch Dermatol. 2008; 144: 886–892.
   PubMed Web of Science ®Google Scholar
• Gomez P, Lacouture ME. Clinical presentation and management of hand-foot skin reaction associated with sorafenib in combination with cytotoxic chemotherapy: experience in breast cancer. Oncologist. 2011; 16: 1508–1519.
   PubMed Web of Science ®Google Scholar
• Jain L, Gardner ER, Figg WD, et al. Lack of association between excretion of sorafenib in sweat and hand-foot skin reaction. Pharmacotherapy. 2010; 30: 52–56.
   PubMed Web of Science ®Google Scholar
• Azad NS, Aragon-Ching JB, Dahut WL, et al. Hand-foot skin reaction increases with cumulative sorafenib dose and with combination anti-vascular endothelial growth factor therapy. Clin Cancer Res. 2009; 15: 1411–1416.
   PubMed Web of Science ®Google Scholar
• Anderson R, Jatoi A, Robert C, et al. Search for evidence-based approaches for the prevention and palliation of hand-foot skin reaction (HFSR) caused by the multikinase inhibitors (MKIs). Oncologist. 2009; 14(3): 291–302.
   PubMed Web of Science ®Google Scholar
• Ren Z, Zhu K, Kang H, et al. Randomized controlled trial of the prophylactic effect of urea-based cream on sorafenib-associated hand-foot skin reactions in patients with advanced hepatocellular carcinoma. J Clin Oncol. 2015; 33: 894–900.
   PubMed Web of Science ®Google Scholar
• Chen AP, Setser A, Anadkat MJ, et al. Grading dermatologic adverse events of cancer treatments: the Common Terminology Criteria for Adverse Events Version 4.0. J Am Acad Dermatol. 2012; 67: 1025–1039.
   PubMed Web of Science ®Google Scholar
• NCI-CTCAE. Version 4.0. Available online at: http://evs.nci.nih.gov/ftp1/CTCAE/About.html. Accessed August 13, 2018.
   Google Scholar
• Winther D, Saunte DM, Knap M, et al. Nail changes due to docetaxel—a neglected side effect and nuisance for the patient. Support Care Cancer. 2007; 15: 1191–1197.
   Web of Science ®Google Scholar
• Wasner G, Hilpert F, Baron R, Pfisterer J. Clinical picture: nail changes secondary to docetaxel. Lancet. 2001; 357: 910.
   PubMed Web of Science ®Google Scholar
• Scotte F, Banu E, Medioni J, et al. Matched case-control phase 2 study to evaluate the use of a frozen sock to prevent docetaxel-induced onycholysis and cutaneous toxicity of the foot. Cancer. 2008; 112: 1625–1631.
   PubMed Web of Science ®Google Scholar
• Borecky DJ, Stephenson JJ, Keeling JH, Vukelja SJ. Idarubicin-induced pigmentary changes of the nails. Cutis. 1997; 59(4): 203–204.
   Web of Science ®Google Scholar
• Shu KY, Kindler HL, Medenica M, Lacouture M. Doxycycline for the treatment of paronychia induced by the epidermal growth factor receptor inhibitor cetuximab. Br J Dermatol. 2006; 154: 191–192.
   Web of Science ®Google Scholar
• Lacouture ME, Anadkat MJ, Bensadoun RJ, et al. Clinical practice guidelines for the prevention and treatment of EGFR inhibitor-associated dermatologic toxicities. Support Care Cancer. 2011; 19: 1079–1095.
   PubMed Web of Science ®Google Scholar
• Ghodsi SZ, Raziei M, Taheri A, et al. Comparison of cryotherapy and curettage for the treatment of pyogenic granuloma: a randomized trial. Br J Dermatol. 2006; 154: 671–675.
   PubMed Web of Science ®Google Scholar
• Quitkin HM, Rosenwasser MP, Strauch RJ. The efficacy of silver nitrate cauterization for pyogenic granuloma of the hand. J Hand Surg Am. 2003; 28: 435–438.
   PubMed Web of Science ®Google Scholar
• Johnston JB, Navaratnam S, Pitz MW, et al. Targeting the EGFR pathway for cancer therapy. Curr Med Chem. 2006; 13: 3483–3492.
   PubMed Web of Science ®Google Scholar
• Perez-Soler R, Delord JP, Halpern A, et al. HER1/EGFR inhibitor-associated rash: future directions for management and investigation outcomes from the HER1/EGFR inhibitor rash management forum. Oncologist. 2005; 10(5): 345–356.
   PubMed Web of Science ®Google Scholar
• Kari C, Chan TO, Rocha de Quadros M, Rodeck U. Targeting the epidermal growth factor receptor in cancer: apoptosis takes center stage. Cancer Res. 2003; 63: 1–5.
   PubMed Web of Science ®Google Scholar
• Saltz LB, Meropol NJ, Loehrer PJ, et al. Phase II trial of cetuximab in patients with refractory colorectal cancer that expresses the epidermal growth factor receptor. J Clin Oncol. 2004; 22: 1201–1208.
   PubMed Web of Science ®Google Scholar
• Wacker B, Nagrani T, Weinberg J, et al. Correlation between development of rash and efficacy in patients treated with the epidermal growth factor receptor tyrosine kinase inhibitor erlotinib in two large phase III studies. Clin Cancer Res. 2007; 13: 3913–3921.
   PubMed Web of Science ®Google Scholar
• Rosen AC, Case EC, Dusza SW, et al. Impact of dermatologic adverse events on quality of life in 283 cancer patients: a questionnaire study in a dermatology referral clinic. Am J Clin Dermatol. 2013; 14: 327–333.
   PubMed Web of Science ®Google Scholar
• Hassel JC, Kripp M, Al-Batran S, Hofheinz RD. Treatment of epidermal growth factor receptor antagonist-induced skin rash: results of a survey among German oncologists. Onkologie. 2010; 33(3): 94–98.
   Google Scholar
• Lacouture ME, Mitchell EP, Piperdi B, et al. Skin toxicity evaluation protocol with panitumumab (STEPP), a phase II, open-label, randomized trial evaluating the impact of a pre-emptive skin treatment regimen on skin toxicities and quality of life in patients with metastatic colorectal cancer. J Clin Oncol. 2010; 28: 1351–1357.
   PubMed Web of Science ®Google Scholar
• Bidoli P, Cortinovis DL, Colombo I, et al. Isotretinoin plus clindamycin seem highly effective against severe erlotinib-induced skin rash in advanced non-small cell lung cancer. J Thorac Oncol. 2010; 5: 1662–1663.
   Web of Science ®Google Scholar
• Requena C, Llombart B, Sanmartin O. Acneiform eruptions induced by epidermal growth factor receptor inhibitors: treatment with oral isotretinoin. Cutis. 2012; 90(2): 77–80.
   Web of Science ®Google Scholar
• Vezzoli P, Marzano AV, Onida F, et al. Cetuximab-induced acneiform eruption and the response to isotretinoin. Acta Derm Venereol. 2008; 88: 84–86.
   Web of Science ®Google Scholar
• Gutzmer R, Werfel T, Mao R, et al. Successful treatment with oral isotretinoin of acneiform skin lesions associated with cetuximab therapy. Br J Dermatol. 2005; 153: 849–851.
   Web of Science ®Google Scholar
• Lacouture ME, Wu S, Robert C, et al. Evolving strategies for the management of hand-foot skin reaction associated with the multitargeted kinase inhibitors sorafenib and sunitinib. Oncologist. 2008; 13: 1001–1011.
   PubMed Web of Science ®Google Scholar
• Drucker AM, Wu S, Dang CT, Lacouture ME. Risk of rash with the anti-HER2 dimerization antibody pertuzumab: a meta-analysis. Breast Cancer Res Treat. 2012; 135: 347–354.
   PubMed Web of Science ®Google Scholar
• Sheu J, Hawryluk EB, Litsas G, et al. Papulopustular acneiform eruptions resulting from trastuzumab, a HER2 inhibitor. Clin Breast Cancer. 2015; 15: e77–e81.
   Google Scholar
• Ensslin CJ, Rosen AC, Wu S, Lacouture ME. Pruritus in patients treated with targeted cancer therapies: systematic review and meta-analysis. J Am Acad Dermatol. 2013; 69: 708–720.
   PubMed Web of Science ®Google Scholar
• Peuvrel L, Bachmeyer C, Reguiai Z, et al. Semiology of skin toxicity associated with epidermal growth factor receptor (EGFR) inhibitors. Support Care Cancer. 2012; 20: 909–921.
   PubMed Web of Science ®Google Scholar
• Inami Y, Andoh T, Sasaki A, Kuraishi Y. Topical surfactant-induced pruritus: involvement of histamine released from epidermal keratinocytes. J Pharmacol Exp Ther. 2013; 344: 459–466.
   Web of Science ®Google Scholar
• Gerber PA, Buhren BA, Cevikbas F, et al. Preliminary evidence for a role of mast cells in epidermal growth factor receptor inhibitor-induced pruritus. J Am Acad Dermatol. 2010; 63: 163–165.
   Web of Science ®Google Scholar
• Lee HG, Grossman SK, Valdes-Rodriguez R, et al. Topical ketamine-amitriptylinelidocaine for chronic pruritus: A retrospective study assessing efficacy and tolerability. J Am Acad Dermatol. 2017; 76: 760–761.
   PubMed Web of Science ®Google Scholar
• Yosipovitch G. Chronic pruritus: a paraneoplastic sign. Dermatol Ther. 2010; 23: 590–596.
   PubMed Web of Science ®Google Scholar
• Mariotto AB, Rowland JH, Yabroff KR, et al. Long-term survivors of childhood cancers in the United States. Cancer Epidemiol Biomarkers Prev. 2009; 18: 1033–1040.
   PubMed Web of Science ®Google Scholar
• Bhatia S, Sklar C. Second cancers in survivors of childhood cancer. Nat Rev Cancer. 2002; 2(2): 124–132.
   Web of Science ®Google Scholar
• Oeffinger KC, Bhatia S. Second primary cancers in survivors of childhood cancer. Lancet. 2009; 374: 1484–1485.
   PubMed Web of Science ®Google Scholar
• Oeffinger KC, Baxi SS, Novetsky Friedman D, Moskowitz CS. Solid tumor second primary neoplasms: who is at risk, what can we do? Semin Oncol. 2013; 40: 676–689.
   Web of Science ®Google Scholar
• Children's Oncology Group. Long-term follow-up guidelines for survivors of childhood, adolescent, and young adult cancers, version 4.0. Available online at: http://survivorshipguidelines.org. Last accessed August 13, 2018.
   Google Scholar
• Nathan PC, Ness KK, Mahoney MC, et al. Screening and surveillance for second malignant neoplasms in adult survivors of childhood cancer: a report from the childhood cancer survivor study. Ann Intern Med. 2010; 153: 442–451.
   Web of Science ®Google Scholar
• Macdonald JB, Macdonald B, Golitz LE, LoRusso P, Sekulic A. Cutaneous adverse effects of targeted therapies: part II: inhibitors of intracellular molecular signaling pathways. J Am Acad Dermatol. 2015; 72: 221–236; quiz 237-238.
   PubMed Web of Science ®Google Scholar
• Poulikakos PI, Persaud Y, Janakiraman M, et al. RAF inhibitor resistance is mediated by dimerization of aberrantly spliced BRAF(V600E). Nature. 2011; 480: 387–390.
   PubMed Web of Science ®Google Scholar
• Sanchez-Laorden B, Viros A, Girotti MR, et al. BRAF inhibitors induce metastasis in RAS mutant or inhibitor-resistant melanoma cells by reactivating MEK and ERK signaling. Sci Signal. 2014; 7(318): ra30.
   Web of Science ®Google Scholar
• Su F, Viros A, Milagre C, et al. RAS mutations in cutaneous squamous-cell carcinomas in patients treated with BRAF inhibitors. N Engl J Med. 2012; 366(3): 207–215.
   PubMed Web of Science ®Google Scholar
• Chu EY, Wanat KA, Miller CJ, et al. Diverse cutaneous side effects associated with BRAF inhibitor therapy: a clinicopathologic study. J Am Acad Dermatol. 2012; 67: 1265–1272.
   PubMed Web of Science ®Google Scholar
• Anforth RM, Blumetti TC, Kefford RF, et al. Cutaneous manifestations of dabrafenib (GSK2118436): a selective inhibitor of mutant BRAF in patients with metastatic melanoma. Br J Dermatol. 2012; 167: 1153–1160.
   PubMed Web of Science ®Google Scholar
• Harvey NT, Millward M, Wood BA. Squamoproliferative lesions arising in the setting of BRAF inhibition. Am J Dermatopathol. 2012; 34: 822–826.
   PubMed Web of Science ®Google Scholar
• Kanti V, Nuwayhid R, Lindner J, et al. Analysis of quantitative changes in hair growth during treatment with chemotherapy or tamoxifen in patients with breast cancer: a cohort study. Br J Dermatol. 2014; 170: 643–650.
   Web of Science ®Google Scholar
• Cho J, Choi EK, Kim IR, et al. Development and validation of Chemotherapy-Induced Alopecia Distress Scale (CADS) for breast cancer patients. Ann Oncol. 2014; 25: 346–351.
   PubMed Web of Science ®Google Scholar
• Olsen EA. Chemotherapy-induced alopecia: overview and methodology for characterizing hair changes and regrowth. In: Olver I, ed. The MASCC Textbook of Cancer Supportive Care and Survivorship. Boston, MA: Springer; 2010: 381–386.
   Google Scholar
• Yeager CE, Olsen EA. Treatment of chemotherapy-induced alopecia. Dermatol Ther. 2011; 24: 432–442.
   PubMed Web of Science ®Google Scholar
• Choi M, Kim MS, Park SY, et al. Clinical characteristics of chemotherapy-induced alopecia in childhood. J Am Acad Dermatol. 2014; 70: 499–505.
   Web of Science ®Google Scholar
• Saggar V, Wu S, Dickler MN, Lacouture ME. Alopecia with endocrine therapies in patients with cancer. Oncologist. 2013; 18: 1126–1134.
   PubMed Web of Science ®Google Scholar
• Duvic M, Lemak NA, Valero V, et al. A randomized trial of minoxidil in chemotherapy-induced alopecia. J Am Acad Dermatol. 1996; 35: 74–78.
   PubMed Web of Science ®Google Scholar
• Granai CO, Frederickson H, Gajewski W, et al. The use of minoxidil to attempt to prevent alopecia during chemotherapy for gynecologic malignancies. Eur J Gynaecol Oncol. 1991; 12(2): 129–132.
   Google Scholar
• Rodriguez R, Machiavelli M, Leone B, et al. Minoxidil (Mx) as a prophylaxis of doxorubicin-induced alopecia. Ann Oncol. 1994; 5: 769–770.
   PubMed Web of Science ®Google Scholar
• Trüeb RM. Chemotherapy-induced alopecia. Semin Cutan Med Surg. 2009; 28: 11–14.
   PubMed Web of Science ®Google Scholar
• Macduff C, Mackenzie T, Hutcheon A, et al. The effectiveness of scalp cooling in preventing alopecia for patients receiving epirubicin and docetaxel. Eur J Cancer Care (Engl). 2003; 12(2): 154–161.
   Web of Science ®Google Scholar
• Shaw J, Baylock B, O'Reilly A, et al. Scalp cooling: a qualitative study to assess the perceptions and experiences of Australian patients with breast cancer. Support Care Cancer. 2016; 24: 3813–3820.
   PubMed Web of Science ®Google Scholar
• Peck HJ, Mitchell H, Stewart AL. Evaluating the efficacy of scalp cooling using the Penguin Cold Cap system to reduce alopecia in patients undergoing chemotherapy for breast cancer. Eur J Oncol Nurs. 2000; 4(4): 246–248.
   PubMedGoogle Scholar
• Lemieux J, Amireault C, Provencher L, Maunsell E. Incidence of scalp metastases in breast cancer: a retrospective cohort study in women who were offered scalp cooling. Breast Cancer Res Treat. 2009; 118: 547–552.
   PubMed Web of Science ®Google Scholar
• Lemieux J, Provencher L, Perron L, et al. No effect of scalp cooling on survival among women with breast cancer. Breast Cancer Res Treat. 2015; 149: 263–268.
   PubMed Web of Science ®Google Scholar
• Food and Drug Administration, HHS. Medical devices; general and plastic surgery devices; classification of the scalp cooling system to reduce the likelihood of chemotherapy-induced alopecia. Final order. Fed Regist. 2016; 81: 7452–7454.
   Google Scholar
• Shah VV, Wikramanayake TC, DelCanto GM, et al. Scalp hypothermia as a preventative measure for chemotherapy-induced alopecia: a review of controlled clinical trials. J Eur Acad Dermatol Venereol. 2018; 32: 720–734.
   Web of Science ®Google Scholar
• Nangia J, Wang T, Osborne C, et al. Effect of a scalp cooling device on alopecia in women undergoing chemotherapy for breast cancer: the SCALP randomized clinical trial. JAMA. 2017; 317: 596–605.
   PubMed Web of Science ®Google Scholar